52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

Nektar reported encouraging 52-week Phase 2b REZOLVE-AA extension data for rezpegaldesleukin in severe-to-very-severe alopecia areata, with 29% of low-dose and 31% of high-dose patients achieving new SALT ≤20 responses from week 36 to week 52. At week 52, SALT ≤20 rates rose to 25.8% and 27.6% in the two active arms versus 6.7% for placebo, while SALT30 and SALT50 responses also improved and safety remained favorable with 94% completing the extension. The results support advancement into late-stage development and could modestly lift NKTR shares, though this is still early-stage clinical data.

Analysis

This read-through is more important for Nektar’s valuation than the absolute response rate headline implies. The key signal is duration: efficacy is still improving after the induction window, which raises the probability that the asset’s commercial profile is meaningfully better than the market would infer from a 36-week snapshot. In immunology, that matters because reimbursement and prescribing behavior are driven by durable hair regrowth plus tolerability, and the absence of late toxicity reduces the odds that payers will force a narrow niche label.

The second-order effect is competitive, not just clinical. If this mechanism can be positioned as a lower-burden biologic versus chronic JAK use, it creates a segmentation wedge in a market where physicians are likely to reserve JAKs for faster but riskier salvage and use this agent earlier for patients prioritizing safety. That could pressure incumbent AA franchises on persistence and physician mindshare even before broad launch, especially if later-stage data reproduce the extension pattern and support a first-line narrative.

The main bear case is that this is still enriched, post-hoc-looking biology in a small extension cohort, so the commercial optionality is being priced against a lot of execution risk. The market will likely care less about statistical significance and more about whether week-52 durability survives a clean registrational design, broader severity mix, and real-world adherence once the novelty effect fades. Over the next 3-9 months, the stock should trade as a catalyst vehicle: upside into conference presentation/late-stage initiation, but vulnerable to a sharp reset if management over-promises market size or if the data package is perceived as too narrow for a premium immunology valuation.

Key Decisions for Investors

• Go long NKTR on a 1-3 month catalyst trade ahead of conference presentation/late-stage trial disclosures; risk/reward is attractive if the market re-rates durability, but size modestly because the asset is still pre-registrational.
• Buy NKTR call spreads or call options with 3-6 month expiry to express upside convexity into the next data readout; define risk tightly given binary execution risk and small-cap biotech volatility.
• If already long NKTR, trim into strength after the initial sympathy move and re-add on any pullback tied to concerns about small extension n, since the valuation should remain headline-sensitive until registrational data land.
• Pair trade: long NKTR vs short a basket of higher-safety-risk AA exposure where chronic JAK economics are more vulnerable to a safer biologic narrative; this isolates mechanism-of-action differentiation rather than broad biotech beta.
• Watch for a post-conference sell-the-news setup; if the stock rerates >15-20% on presentation headlines without new confirmatory data, fade part of the move because the extension signal is supportive but not yet self-sustaining.